Switching to nebulised short acting bronchodilators does not increase the risk of arrhythmia in patients hospitalized with a COPD exacerbation

Santus, Pierachille; Franceschi, Elisa; Pini, Stefano; Frassanito, Francesca; Amati, Francesco; Danzo, Fiammetta; Gatti, Marina; Radovanovic, Dejan

doi:10.1016/j.phrs.2021.105915

Cited by 2 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ipratropium bromide is an anticholinergic drug with high selectivity for M receptors of bronchial smooth muscle. It can relax bronchial smooth muscle, reduce mucus secretion and tissue edema, and has little impact on respiratory glands and the cardiovascular system [12][13][14]. Reportedly, it can promote the ciliary movement of the bronchial mucosa and facilitate the discharge of sputum [15].…”

Section: Discussionmentioning

confidence: 99%

Compound Ipratropium Bromide plus Budesonide Inhalation in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Its Effect on Heparin-Binding Protein

Dong

2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To analyze the clinical effect of compound ipratropium bromide combined with budesonide atomization inhalation on acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and its effect on the heparin-binding protein. Methods. A total of 110 patients with AECOPD who were admitted to our hospital between January 2020 and January 2021 were enrolled and assigned into control group (conventional treatment + compound ipratropium bromide) and combined group (conventional treatment + compound ipratropium bromide + budesonide) in a 1 : 1 ratio according to different treatment methods. The clinical effects, pulmonary function indexes, and heparin-binding protein levels before and after treatment were compared between the two groups. Results. The treatment with oxygen-driven nebulization of ipratropium bromide combined with budesonide led to a significantly higher total effective rate versus the treatment with ipratropium bromide alone ( P < 0.001 ). After treatment, remarkably higher arterial oxygen partial pressure (PaO2), arterial oxygen saturation (SaO2), forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and FEV1/FVC in the combined group vs. the control group were observed ( P < 0.001 ). The carbon dioxide partial pressure (PaCO2) levels in the two groups were significantly lower than those before treatment, and the decrease in the combined group was greater ( P < 0.001 ). A significantl reduction was observed in heparin-binding protein in both groups after treatment, and the decrease in the combined group was greater versus the control group ( P < 0.001 ). Conclusion. Compound ipratropium bromide plus budesonide via aerosol inhalation therapy might be a preferable approach for AECOPD patients. It exhibits a synergistic effect on inhibiting inflammatory mediators and cytokine networks, significantly reduces airway hyperresponsiveness, and improves blood gas indicators and lung function.

show abstract

Section: Discussionmentioning

confidence: 99%